Supernus stock surges on FDA approval
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) climbed 5.5% Tuesday as the U.S. Food and Drug Administration approved ...
Zacks.com on MSN22h
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade
Supernus (SUPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Supernus stock price target raised to $44 at TD Cowen
Supernus Pharmaceuticals (NASDAQ:SUPN) stock received a price target increase from TD Cowen, with the target moving up to $44.00 from the previous $43.00. The firm maintained a Buy rating on the ...
Investing10d
Supernus stock surges on FDA approval
In response to the approval, TD Cowen analyst Stacy Ku, Ph.D. raised the price target on Supernus Pharmaceuticals to $44.00 from $43.00 while maintaining a Buy rating. "The FDA has approved Onapgo ...
Nasdaq7d
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade
As such, the Zacks rating upgrade for Supernus is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price. The change in a company's future ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pfizer (PFE) and Supernus Pharmaceuticals (SUPN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report) and Supernus ...
Wall Street Journal7d
Supernus Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...